KNSA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.06
Percentage change 0.30	%

Peers: AMGN REGN BIIB VRTX GILD INCY BMRN NBIX EXEL SAGE

| Held by: VTI IWM VB VBR IWO VBK IBB VTWO VHT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.14	Insider Own	45.00%	Shs Outstand	41.52M	Perf Week	-6.09%
Market Cap	1.46B	Forward P/E	41.09	EPS next Y	0.49	Insider Trans	-1.58%	Shs Float	39.71M	Perf Month	-10.70%
Income	-9.07M	PEG	-	EPS next Q	0.03	Inst Own	55.68%	Short Float	10.12%	Perf Quarter	-19.71%
Sales	384.10M	P/S	3.81	EPS this Y	-290.98%	Inst Trans	1.90%	Short Ratio	11.13	Perf Half Y	7.62%
Book/sh	6.06	P/B	3.34	EPS next Y	228.72%	ROA	-1.75%	Short Interest	4.02M	Perf Year	15.03%
Cash/sh	3.09	P/C	6.54	EPS next 5Y	-	ROE	-2.15%	52W Range	16.56 - 28.15	Perf YTD	15.17%
Dividend Est.	-	P/FCF	131.79	EPS past 5Y	-	ROI	-2.04%	52W High	-28.24%	Beta	0.27
Dividend TTM	-	Quick Ratio	2.95	Sales past 5Y	98.80%	Gross Margin	60.88%	52W Low	21.98%	ATR (14)	0.81
Dividend Ex-Date	-	Current Ratio	3.24	EPS Y/Y TTM	-30.39%	Oper. Margin	-6.83%	RSI (14)	33.35	Volatility	3.31% 3.50%
Employees	297	Debt/Eq	0.02	Sales Y/Y TTM	54.41%	Profit Margin	-2.36%	Recom	1.00	Target Price	36.00
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	10.33%	Payout	0.00%	Rel Volume	0.53	Prev Close	20.14
Sales Surprise	0.63%	EPS Surprise	-872.53%	Sales Q/Q	67.37%	Earnings	Oct 29 BMO	Avg Volume	360.98K	Price	20.20
SMA20	-5.25%	SMA50	-13.29%	SMA200	-7.84%	Trades		Volume	192,503	Change	0.30%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-13-24	Initiated	Jefferies	Buy	$40
May-03-24	Initiated	Wells Fargo	Overweight	$34
Jun-29-20	Reiterated	BofA Securities	Buy	$25 → $40
Apr-01-20	Initiated	BofA/Merrill	Buy	$25
Mar-11-19	Initiated	Barclays	Overweight	$26
Dec-12-18	Reiterated	Wedbush	Outperform	$31 → $33
Jun-19-18	Initiated	JMP Securities	Mkt Outperform	$33

Nov-26-24 04:01PM	Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-13-24 10:45AM	Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-12-24 04:01PM	Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-30-24 04:25AM	Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ... (GuruFocus.com)
08:45AM	Loading…
Oct-29-24 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -15.68%
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-28-24 09:05AM	What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings (GuruFocus.com)
08:00AM	Kiniksa Pharmaceuticals Partners with GRAMMY Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Oct-22-24 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 (GlobeNewswire)
Oct-09-24 09:55AM	Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet (Zacks)
Oct-08-24 09:10PM	Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals (GuruFocus.com)
Oct-01-24 08:00AM	NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Aug-28-24 04:01PM	Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-05-24 09:55AM	Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade (Zacks)
12:00PM	Loading…
Jul-26-24 12:00PM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why (Zacks)
Jul-23-24 08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +22.91%
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-16-24 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 (GlobeNewswire)
Jul-09-24 08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjogren's Disease (GlobeNewswire)
08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sj gren's Disease (GlobeNewswire)
Jun-24-24 08:00AM	Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis (GlobeNewswire)
Jun-17-24 08:30AM	Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative (GlobeNewswire)
Jun-04-24 04:01PM	Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 07:00AM	Sector Spotlight: Orphan Drug Developers With Significant Upside (News Direct)
May-07-24 04:01PM	Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
Apr-24-24 09:00AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-23-24 11:53AM	KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:53AM	Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts (GuruFocus.com)
08:40AM	Loading…
08:40AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:36AM	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Apr-16-24 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024 (GlobeNewswire)
Apr-02-24 07:30AM	Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart (GlobeNewswire)
Mar-01-24 09:55AM	Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect? (Zacks)
Feb-29-24 11:33PM	Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) (GuruFocus.com)
12:00PM	Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice (Zacks)
09:21AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:40AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:52AM	Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Feb-21-24 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 09:55AM	Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know (Zacks)
08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-23-24 09:55AM	How Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93% (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why (Zacks)
Jan-09-24 08:46AM	Is Kiniksa Pharmaceuticals (KNSA) Stock a Solid Choice Right Now? (Zacks)
Jan-04-24 07:30AM	Kiniksa Pharmaceuticals Provides Corporate Update (GlobeNewswire)
Jan-02-24 04:01PM	Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.64% +7.83%
Dec-23-23 09:00AM	Chief Accounting Officer Michael Megna Sells 9,316 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) (GuruFocus.com)
Dec-15-23 02:30PM	The 3 Most Undervalued Biotech Stocks to Buy in December (InvestorPlace) +5.51%
Nov-24-23 02:05PM	Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How (Zacks)
Nov-20-23 09:55AM	Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High? (Zacks)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace) -5.83%
Nov-01-23 08:27AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 10:48PM	Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents)
08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-24-23 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023 (GlobeNewswire)
Oct-20-23 12:08PM	12 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Aug-27-23 08:40AM	13 NASDAQ Stocks with Lowest PE Ratios That May Not Be Value Traps (Insider Monkey)
Aug-22-23 08:14AM	11 Most Undervalued Biotech Stocks to Buy According to Analysts (Insider Monkey)
Aug-18-23 09:04PM	HHLR ADVISORS, LTD. Increases Stake in Kiniksa Pharmaceuticals Ltd (GuruFocus.com)
Aug-10-23 10:33PM	Fairmount Funds Management LLC Acquires New Stake in Kiniksa Pharmaceuticals Ltd (GuruFocus.com)
Aug-07-23 06:14AM	Investing in Kiniksa Pharmaceuticals (NASDAQ:KNSA) a year ago would have delivered you a 41% gain (Simply Wall St.)
Jul-25-23 10:05PM	Q2 2023 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents) +30.39%
01:06PM	Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday (Motley Fool)
08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-24-23 08:31AM	Illumina (ILMN) Soars 3.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-18-23 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023 (GlobeNewswire)
Jul-17-23 08:00AM	Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023 (GlobeNewswire) +5.02%
Jul-04-23 08:24PM	3 Small-Cap Stocks That Are Worth the Gamble (InvestorPlace)
Jun-06-23 04:01PM	Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-03-23 06:14AM	Kiniksa Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.) +8.34%
May-02-23 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.66%
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
May-01-23 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023 (GlobeNewswire)
Apr-09-23 09:21AM	Could The Market Be Wrong About Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Its Attractive Financial Prospects? (Simply Wall St.)
Apr-05-23 01:40PM	7 Thrilling Biotech Stocks for Aggressive Investors to Buy (InvestorPlace)
Mar-31-23 09:35AM	After Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA) (Zacks)
Mar-30-23 02:20PM	7 Small-Cap Stocks to Buy for Explosive Growth Potential (InvestorPlace)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 12:04PM	HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza (Zacks)
Mar-23-23 02:25PM	7 Dirt-Cheap Stocks Sitting in the Sweet Spot (InvestorPlace)
Mar-03-23 06:57PM	The Top 7 Growth Stocks in Biotech (InvestorPlace)
Feb-28-23 11:25AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates (Zacks)
08:00AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Feb-27-23 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023 (GlobeNewswire)
11:47AM	Further weakness as Kiniksa Pharmaceuticals (NASDAQ:KNSA) drops 9.0% this week, taking three-year losses to 32% (Simply Wall St.)
Feb-23-23 10:50AM	13 High Growth Pharma Stocks that are Profitable (Insider Monkey)
Jan-25-23 02:52AM	Allogene Therapeutics (ALLO) Soars 15.7%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-23 04:51PM	10 Best Healthcare Stocks For the Long Term (Insider Monkey)
Jan-09-23 08:00AM	Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update (GlobeNewswire) -7.79%
Jan-03-23 04:01PM	Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-30-22 04:01PM	Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference (GlobeNewswire)
Nov-23-22 04:01PM	Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference (GlobeNewswire)

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 09 '24	Option Exercise	11.10	18,860	209,346	41,818	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 06 '24	Option Exercise	10.76	2,406	25,889	25,364	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 09 '24	Sale	21.38	18,860	403,227	22,958	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 06 '24	Sale	21.27	8,969	190,771	22,958	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 03 '24	Option Exercise	10.76	8,969	96,506	31,927	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 04 '24	Option Exercise	10.76	5,024	54,058	27,982	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 05 '24	Option Exercise	10.76	1,123	12,083	24,081	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 03 '24	Sale	21.45	8,969	192,385	22,958	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 04 '24	Sale	21.25	5,024	106,760	22,958	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 05 '24	Sale	21.25	1,123	23,864	22,958	Dec 05 07:14 PM
Ragosa Mark	Officer	Dec 03 '24	Proposed Sale	21.25	72,754	1,546,022		Dec 03 05:25 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 27 '24	Option Exercise	11.10	8,637	95,871	35,165	Dec 02 04:36 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 29 '24	Option Exercise	11.10	9	100	26,537	Dec 02 04:36 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 27 '24	Sale	22.45	8,637	193,901	26,528	Dec 02 04:36 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 29 '24	Sale	22.45	9	202	26,528	Dec 02 04:36 PM
Megna Michael R	Officer	Nov 27 '24	Proposed Sale	22.45	17,697	397,298		Nov 27 05:13 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 18 '24	Option Exercise	1.59	10,000	15,900	119,975	Nov 20 04:39 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 18 '24	Sale	21.04	17,000	357,680	102,975	Nov 20 04:39 PM
Tessari Eben	Officer	Nov 18 '24	Proposed Sale	21.04	17,000	357,641		Nov 18 05:50 PM
Patel Sanj K	CHAIRMAN & CEO	Nov 06 '24	Option Exercise	1.59	89,561	142,402	169,112	Nov 08 04:34 PM
Patel Sanj K	CHAIRMAN & CEO	Nov 06 '24	Sale	23.00	89,561	2,059,903	79,551	Nov 08 04:34 PM
Patel Sanj K	Officer	Nov 06 '24	Proposed Sale	23.00	89,561	2,060,253		Nov 06 04:11 PM
Tessari Eben	CHIEF OPERATING OFFICER	Oct 15 '24	Option Exercise	1.59	10,000	15,900	126,975	Oct 17 04:35 PM
Tessari Eben	CHIEF OPERATING OFFICER	Oct 15 '24	Sale	26.87	17,000	456,790	109,975	Oct 17 04:35 PM
Tessari Eben	Officer	Oct 15 '24	Proposed Sale	26.87	17,000	456,789		Oct 15 04:57 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 23 '24	Option Exercise	1.59	10,000	15,900	134,475	Sep 25 04:39 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 23 '24	Sale	24.99	17,500	437,325	116,975	Sep 25 04:39 PM
Tessari Eben	Officer	Sep 23 '24	Proposed Sale	24.99	17,500	437,258		Sep 23 05:02 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 02 '24	Option Exercise	0.00	1,964	0	125,052	Sep 04 08:53 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	1.88	60,692	113,809	112,730	Sep 04 08:52 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	26.12	60,692	1,584,991	52,038	Sep 04 08:52 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Sep 03 '24	Option Exercise	10.95	68,506	750,192	90,242	Sep 04 08:42 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Sep 03 '24	Sale	26.12	68,506	1,789,190	21,736	Sep 04 08:42 PM
Moat Ross	Officer	Sep 03 '24	Proposed Sale	26.12	68,506	1,789,288		Sep 03 05:17 PM
Paolini John F.	Officer	Sep 03 '24	Proposed Sale	26.12	90,217	2,356,351		Sep 03 05:16 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 27 '24	Option Exercise	1.59	10,000	15,900	137,411	Aug 29 04:36 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 27 '24	Sale	26.91	17,500	470,925	119,911	Aug 29 04:36 PM
Tessari Eben	Officer	Aug 27 '24	Proposed Sale	26.91	17,500	470,904		Aug 27 05:17 PM
Patel Sanj K	CHAIRMAN & CEO	Jul 23 '24	Option Exercise	1.59	136,124	216,437	199,136	Jul 25 04:33 PM
Patel Sanj K	CHAIRMAN & CEO	Jul 23 '24	Sale	25.65	136,124	3,491,947	63,012	Jul 25 04:33 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jul 23 '24	Option Exercise	11.10	24,248	269,153	43,501	Jul 25 04:32 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jul 23 '24	Sale	24.79	24,248	601,108	19,253	Jul 25 04:32 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Jul 23 '24	Option Exercise	1.86	22,000	40,920	69,803	Jul 25 04:31 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Jul 23 '24	Sale	26.32	22,000	578,966	47,803	Jul 25 04:31 PM
Patel Sanj K	CHAIRMAN & CEO	Mar 07 '24	Sale	21.02	65,012	1,366,552	0	Mar 11 07:05 PM
Patel Sanj K	CHAIRMAN & CEO	Mar 04 '24	Sale	21.49	12,742	273,834	70,594	Mar 06 05:37 PM
Patel Sanj K	CHAIRMAN & CEO	Mar 06 '24	Sale	21.00	5,582	117,222	65,012	Mar 06 05:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Mar 01 '24	Option Exercise	1.59	656	1,043	124,036	Mar 05 04:34 PM
Tessari Eben	CHIEF OPERATING OFFICER	Mar 01 '24	Sale	22.03	1,189	26,194	122,847	Mar 05 04:34 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Mar 01 '24	Option Exercise	1.86	18,844	35,050	62,736	Mar 05 04:31 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Mar 01 '24	Sale	21.77	18,844	410,234	44,892	Mar 05 04:31 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Mar 01 '24	Option Exercise	10.93	9,659	105,560	27,247	Mar 01 06:26 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Feb 28 '24	Option Exercise	8.83	5,126	45,263	22,714	Mar 01 06:26 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Mar 01 '24	Sale	21.45	9,659	207,186	17,588	Mar 01 06:26 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Feb 28 '24	Sale	21.79	5,126	111,696	17,588	Mar 01 06:26 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Feb 27 '24	Option Exercise	1.86	10,156	18,890	55,048	Feb 29 04:26 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Feb 27 '24	Sale	21.03	10,156	213,581	44,892	Feb 29 04:26 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jan 03 '24	Option Exercise	8.83	12,000	105,960	27,632	Jan 04 04:30 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jan 03 '24	Sale	20.00	12,000	240,000	15,632	Jan 04 04:30 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Jan 02 '24	Option Exercise	13.88	16,670	231,380	33,675	Jan 04 04:30 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Jan 02 '24	Sale	19.17	16,670	319,564	17,005	Jan 04 04:30 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Dec 19 '23	Option Exercise	13.88	9,316	129,306	26,321	Dec 21 04:26 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Dec 19 '23	Sale	19.13	9,316	178,215	17,005	Dec 21 04:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Kiniksa Pharmaceuticals International Plc

Upgrade your FINVIZ experience